← All trials
NCT04149106
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2019
- Primary completion
- Oct 30, 2020
- Completion date
- Mar 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 4556
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of the Sciences, Techniques and Technologies of BamakoLead sponsor
- Deakin UniversityCollaborator
- Johns Hopkins UniversityCollaborator
- Tulane UniversityCollaborator
- University of South FloridaCollaborator
- University of CopenhagenCollaborator
- University of the Sciences, Techniques and Technologies of BamakoStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.